Get the Stockscreener App
3.03
6.69%
0.19
After Hours:
3.04
0.01
+0.33%
Absci Corp stock is traded at $3.03, with a volume of 3.22M.
It is up +6.69% in the last 24 hours and up +14.34% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$2.84
Open:
$2.87
24h Volume:
3.22M
Relative Volume:
1.05
Market Cap:
$338.03M
Revenue:
$4.21M
Net Income/Loss:
$-97.67M
P/E Ratio:
-3.2581
EPS:
-0.93
Net Cash Flow:
$-70.76M
1W Performance:
+14.34%
1M Performance:
+14.34%
6M Performance:
-2.57%
1Y Performance:
-30.66%
1-Day Range:
$2.86
$3.07
1-Week Range:
$2.635
$3.07
52-Week Range:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.03 | 338.03M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Two Sigma Investments LP Raises Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Deutsche Bank AG Purchases 28,073 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
Absci (NASDAQ:ABSI) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Absci (NASDAQ:ABSI) Stock Rating Lowered by Wall Street Zen - Defense World
AbSci Corp (ABSI) Sees Borrow Rate Increase | ABSI Stock News - GuruFocus
Woodline Partners LP Decreases Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Northern Trust Corp Has $1.72 Million Stock Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Brokerages Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40 - MarketBeat
Wall Street Zen Upgrades Absci (NASDAQ:ABSI) to Hold - Defense World
Ameriprise Financial Inc. Sells 23,668 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
AbSci Corp (ABSI): Key Indicator Shows Noticeable Increase | ABSI Stock News - GuruFocus
Catherine Wood's Strategic Acquisition of Absci Corp Shares - GuruFocus
Schonfeld Strategic Advisors LLC Has $144,000 Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
Absci Sets Stage for Major AI Breakthroughs at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Needham & Company LLC Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Stifel Financial Corp - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Absci (NASDAQ:ABSI) - Defense World
Absci Corp’s Earnings Call: A Promising Outlook - TipRanks
Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript - Insider Monkey
Absci First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI Stock News - GuruFocus
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 | ABSI Stock News - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101 - GuruFocus
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI S - GuruFocus
Assessing Absci: Insights From 6 Financial Analysts - Benzinga
Absci Corporation Advances Clinical Programs with Strong Q1 Results - TipRanks
Fred Alger Management LLC Reduces Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Reve - GuruFocus
Absci earnings beat by $0.01, revenue fell short of estimates - Investing.com
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings By Investing.com - Investing.com Nigeria
AbSci (ABSI) Anticipates Significant Post-Earnings Movement | AB - GuruFocus
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings - Investing.com
Absci Q1 2025 Earnings Call Transcript - MarketBeat
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiat - GuruFocus
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiatives | ABSI Stock News - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial - TipRanks
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease - marketscreener.com
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease - GlobeNewswire
Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential - Stock Titan
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Has $115,000 Stock Position in Absci Co. (NASDAQ:ABSI) - Defense World
Absci (ABSI) Projected to Post Quarterly Earnings on Tuesday - Defense World
Absci (ABSI) Expected to Announce Earnings on Tuesday - MarketBeat
Mariner LLC Purchases New Stake in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):